Merck & Co., Inc.
NYSEMRK short interest surges 24% in one week to 1.4% of float, driven by activist accumulation ahead of Q2 earnings; cost to borrow remains cheap at 0.34%, with extreme availability at 9,230% of SI suggesting minimal squeeze risk.
Snapshot as of 21 Jun 2026
A new long-form analysis for MRK this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumMRK reported Q1 earnings on May 26. The stock slipped 1.8% on the day. Two days later, options traders are still the most defensively positioned they've been all year. The put/call ratio stands at 0.93 — a fresh…
MRK arrives at Tuesday's Q1 print in a materially different position than it occupied three days ago — the stock has surged 10% over the past week to $122.41, yet options traders have not unwound their defensive…
MRK enters next week's Q1 results — scheduled for May 26 — with options positioning at the most cautious level recorded in the past twelve months. The clearest signal heading into the print is in the options market.…
MRK heads into its next earnings cycle with options traders growing more defensive even as short sellers trim positions — a divergence that defines the week's setup. The clearest signal this week comes from options.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRK — free to start on ORTEX.
Sign up for free →Open MRK on ORTEX